n-Lorem Foundation
Cambridge, Massachusetts, United States · Biotechnology, Health Care, Medical
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines for treating nano-rare patients. These patients are diagnosed with diseases resulting from a single genetic defect unique to only a small number of individuals. By developing individuali
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 33
- Industries
- Biotechnology, Health Care, Medical
- Status
- Private
- Website
- nlorem.org
- Company page
Recent activity at n-Lorem Foundation
Leadership
- Virginia Sankey, Seasoned Financial Executive
- Amy Williford, Senior Director Communications and Donor Relations
- Thuy Nguyen, Experienced Pharmaceutical Professional
- Julie Douville, Executive Director, Aso Discovery and Development
- Andrew Serrano, Digital Marketing Manager
- Stanley Crooke, Founder, Chairman and Chief Executive Officer
- Virginia Sankey, Seasoned Financial Executive
- Amy Williford, Senior Director Communications and Donor Relations
- Thuy Nguyen, Experienced Pharmaceutical Professional
- Julie Douville, Executive Director, Aso Discovery and Development
- Andrew Serrano, Digital Marketing Manager
- Stanley Crooke, Founder, Chairman and Chief Executive Officer
Verified email and direct lines for n-Lorem Foundation’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
n-Lorem Foundation files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
n-Lorem Foundation in the news
- n-Lorem Foundation Celebrates Five Years of Bringing Hope and Potential Treatments to Nano-rare Patients - Business Wire (Apr 15, 2025)
- n-Lorem Foundation and Columbia University Establish Silence ALS Initiative - Target ALS (May 03, 2022)
- Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders - PR Newswire (Jun 10, 2026)
- BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome - Finansavisen (Jul 27, 2026)
- Donald Ray Foster Obituary 2024 - McAlister-Smith Funeral & Cremation (Nov 18, 2024)
- Stephen Cooper Obituary - Oceanside, CA - Dignity Memorial (Jun 27, 2025)
- n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapie - AD HOC NEWS (Jan 13, 2026)
Companies similar to n-Lorem Foundation
- Mesothelioma UK · Biotechnology, Health Care, Medical, Non Profit
- Breast Cancer Canada · Biotechnology, Health Care, Medical, Non Profit
- Ascidian Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
- Cancer Research Wales · Biotechnology, Health Care, Medical, Non Profit
- Aptose Biosciences · Biotechnology, Health Care, Medical, Therapeutics
About n-Lorem Foundation: questions and answers
What does n-Lorem Foundation do?
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines for treating nano-rare patients. These patients are diagnosed with diseases resulting from a single genetic defect unique to only a small number of individuals. By developing individuali
Where is n-Lorem Foundation headquartered?
n-Lorem Foundation is headquartered in Cambridge, Massachusetts, United States.
How many employees does n-Lorem Foundation have?
n-Lorem Foundation has about 33 employees.
Who leads n-Lorem Foundation?
Stanley Crooke is a Founder, Chairman and Chief Executive Officer at n-Lorem Foundation.
What is the latest news on n-Lorem Foundation?
On Jan 12, 2026, n-Lorem Foundation and EspeRare Foundation Announce European Partnership to Enhance Access to ASO Therapies for Rare Genetic Diseases.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy